100 years of serving patients: our Gödöllő plant celebrates a century of history
Sixteen years ago, we took over the legacy of a pioneering vaccines and blood derivatives company in Hungary
Kedrion Biopharma joins Rare Disease Day
Raising awareness and generating change for the people living with a rare disease
Permira Funds and the Marcucci family complete investment in Kedrion & BPL
Announced appointment of Ugo Di Francesco as CEO
Results of the “Words in Hemophilia: Towards Patient Engagement” study have been published
The project supported by Kedrion defines some of the key principles intended to improve patient envolvement
Kedrion and LFB sign industrial cooperation agreement
Scope is supplying Immunoglobulins to meet patient demand in France
KIDCARES10, First Patient Treated in Pediatric PI Study
Kedrion stronger in North America and further committed to rare diseases
Agreement with Canadian-based Liminal BioSciences signed on June 22nd
KIDCARES10, first patient enrolled in pediatric PI study
Thirty patients aged 2 to 17 years old to be enrolled over five European countries
KEDPLASMA ANNOUNCEMENT
HUMAN BioPlazma Kft. – a subsidiary of Kedrion Biopharma – informs that, as of February 1st, 2021, all its KEDPLASMA plasma collection centers in Hungary will be operating under a new owner, Haema Plasma Kft. Through HUMAN BioPlazma Kft., Kedrion Biopharma will continue to operate in the country with the distribution of plasma-derived medicinal products.
Kedrion announces the appointment of a new CEO
Val Romberg from the USA, one of the most esteemed managers in the industry
